EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access

Comparison of direct oral anticoagulants and warfarin in chronic limb-threatening ischemia

Matthew Rockhold, Lauren Kunkel, Jordan L Lacoste, Thomas Szymanski, Paul Rothenberg, Pamela Zimmerman, Samantha Minc

Journal of Vascular Surgery · 2024-06 · 79 (6) · 1466-1472.e1

DOI: 10.1016/j.jvs.2024.01.196 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Vascular Surgery, 2024-06. Verfasst von Matthew Rockhold und 6 weiteren Autor:innen. Beteiligte Einrichtung: West Virginia University Medicine, Department of Pharmacy, Morgantown, WV. Electronic address: matthew.rockhold@wvumedicine.org. Hauptthemen laut MEDLINE: Warfarin, Pyridones, Anticoagulants, Amputation, Surgical. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The role of direct oral anticoagulants (DOACs) in chronic limb-threatening ischemia after revascularization is unknown. Current evidence-based guidelines do not provide clear guidance on the role of anticoagulation or the selection of anticoagulant. Current practice is highly varied and based on provider and patient preference. The purpose of this study was to measure the impact of different anticoagulants on the incidence of major adverse limb events (MALEs) after revascularization for chronic limb-threatening ischemia, major adverse cardiovascular events (MACEs), all-cause mortality, and hospitalization for major bleeding events. METHODS: This was a single-center, observational, retrospective cohort study. Subjects were eligible if they were 18 years or older; underwent endovascular or open revascularization for chronic limb-threatening ischemia, rest pain, or tissue loss; and were subsequently prescribed apixaban, rivaroxaban, or warfarin. The primary end point was the incidence of MALEs, including above-ankle amputation or major index-limb reintervention, within 1 year of index event. Secondary end points included the rate of all-cause mortality, MACEs, and incidence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding. RESULTS: From January 1, 2017, to September 20, 2022, 141 patients met the inclusion and exclusion criteria and were reviewed. The median age was 67 years, with 92 patients prescribed apixaban or rivaroxaban and 49 patients prescribed warfarin. Of these, 42 patients were prescribed triple antithrombotic therapy, 88 dual antithrombotic therapy, and 13 anticoagulant monotherapy. The primary outcome of 1-year MALEs occurred in 36.7% of the warfarin group and 33.7% of the DOAC group (relative risk [RR], 1.09; 95% CI, 0.53-2.25; P = .72). Secondary outcomes of 1-year MACEs (10.2% vs 4.3%; RR, 2.35; 95% CI, 0.60-9.18; P = .18) and 1-year all-cause mortality (26.5% vs 16.3%; RR, 1.63; 95% CI, 0.70-3.78; P = .15) did not differ between the groups. The secondary safety outcome of 1-year ISTH major bleeding occurred in 16.3% of the warfarin group and 4.3% of the DOAC group (RR, 3.76; 95% CI, 1.07-13.19; P = .015). CONCLUSIONS: In patients with chronic limb-threatening ischemia who were revascularized and prescribed anticoagulation with apixaban, rivaroxaban, or warfarin on discharge, no difference in MALEs, MACEs, or all-cause mortality was found. However, 1-year admissions for ISTH major bleeding were significantly higher among patients prescribed warfarin. A randomized trial may confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WarfarinPyridonesAnticoagulantsAmputation, SurgicalHemorrhagePyrazolesRivaroxabanHumansMaleFemaleAgedRetrospective StudiesAdministration, OralTreatment OutcomeMiddle AgedTime FactorsRisk FactorsChronic Limb-Threatening IschemiaAged, 80 and overFactor Xa InhibitorsPeripheral Arterial DiseaseRisk AssessmentLimb SalvageVascular Surgical ProceduresEndovascular Procedures

Stichwörter der Autor:innen

AnticoagulantsChronic limb-threatening ischemiaLimb ischemiaPeripheral artery diseaseReperfusion

Substanzen

WarfarinPyridonesAnticoagulantsapixabanPyrazolesRivaroxabanFactor Xa Inhibitors

Autor:innen und Institutionen

  • West Virginia University Medicine, Department of Pharmacy, Morgantown, WV. Electronic address: matthew.rockhold@wvumedicine.org.
  • West Virginia University Medicine, Department of Pharmacy, Morgantown, WV.
  • West Virginia University Medicine, Department of General Surgery, Morgantown, WV.
  • West Virginia University Medicine, Department of Vascular Surgery, Morgantown, WV.

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health

Zitieren

APA

Rockhold, M., Kunkel, L., Lacoste, J. L., Szymanski, T., Rothenberg, P., Zimmerman, P., & Minc, S. (2024). Comparison of direct oral anticoagulants and warfarin in chronic limb-threatening ischemia. Journal of Vascular Surgery, 79(6), 1466-1472.e1. https://doi.org/10.1016/j.jvs.2024.01.196

Vancouver

Rockhold M, Kunkel L, Lacoste JL, Szymanski T, Rothenberg P, Zimmerman P, et al. Comparison of direct oral anticoagulants and warfarin in chronic limb-threatening ischemia. Journal of Vascular Surgery. 2024;79(6):1466-1472.e1. doi:10.1016/j.jvs.2024.01.196

BibTeX
@article{Rockhold2024,
  author = {Rockhold, Matthew and Kunkel, Lauren and Lacoste, Jordan L and Szymanski, Thomas and Rothenberg, Paul and Zimmerman, Pamela and Minc, Samantha},
  title = {Comparison of direct oral anticoagulants and warfarin in chronic limb-threatening ischemia},
  journal = {Journal of Vascular Surgery},
  year = {2024},
  volume = {79},
  number = {6},
  pages = {1466--1472.e1},
  doi = {10.1016/j.jvs.2024.01.196}
}
Kostenlos starten →